TrialPath
ALS (Lou Gehrig's disease) · Houston

ALS (Lou Gehrig's disease) clinical trials in Houston

7 recruiting amyotrophic lateral sclerosis studies within range of Houston. Click any trial for full eligibility criteria and contact info.

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

Recruiting

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

PhasePhase 3
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 55 more
SponsorPrilenia
▾Tap for details
Apply

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Recruiting

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

PhasePhase 2
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 48 more
SponsorZydus Therapeutics Inc.
▾Tap for details
Apply

BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia

NCT00912041 · Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis
Recruiting

The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.

PhaseNA
TypeInterventional
Age18 Years – 80 Years
WhereSacramento, California, United States + 5 more
SponsorLeigh R. Hochberg, MD, PhD.
▾Tap for details
Apply

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

NCT04363684 · Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD)
Recruiting

ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.

Phase—
TypeObservational
Age18 Years
WhereBirmingham, Alabama, United States + 25 more
SponsorMayo Clinic
▾Tap for details
Apply

AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis

NCT06665165 · ALS
Recruiting

This study is a placebo-controlled Phase I study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the antisense oligonucleotide (ASO) AMX0114 in adult participants with amyotrophic lateral sclerosis (ALS).

PhasePhase 1
TypeInterventional
Age18 Years
WhereLa Jolla, California, United States + 13 more
SponsorAmylyx Pharmaceuticals Inc.
▾Tap for details
Apply

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures

NCT05137665 · Amyotrophic Lateral Sclerosis, Movement Disorders, Degenerative Disorder
Recruiting

The goal of the study is to generate a biorepository of longitudinal biofluids-blood (plasma and serum), cerebral spinal fluid (CSF) and urine linked to genetics and longitudinal clinical information that are made available to the research community. To accomplish these goals, we will enroll 800 Amyotrophic Lateral Sclerosis (ALS) patients and 200 healthy controls from sites globally, over a 5 year time frame. Additionally, speech and motor function and spirometry measures will be collected bi-weekly in a subset of participants. ALS participants will be asked to come to the clinic for 5 study visits approximately every 4 months. Healthy participants will be coming for 2 study visits with a 12-month interval between visits. These samples and clinical information will be stored in a de-identified manner and made available for investigators to use in future research studies.

Phase—
TypeObservational
Age18 Years
WherePhoenix, Arizona, United States + 11 more
SponsorTarget ALS Foundation, Inc.
▾Tap for details
Apply

A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Recruiting

The primary objective of this dose-finding study is to evaluate the safety, tolerability and pharmacodynamics of single dose of INS1202 via IT administration in participants ≥ 18 to \<80 years of age with ALS who carry superoxide dismutase type 1 (SOD1) mutations or harbor no known ALS-related genetic mutation.

PhasePhase 1
TypeInterventional
Age18 Years – 79 Years
WherePhoenix, Arizona, United States + 8 more
SponsorInsmed Gene Therapy LLC
▾Tap for details
Apply